New DNA booster shot targets omicron in small trial
NCT ID NCT06436911
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1/2 trial tested a new DNA booster vaccine called Covigenix VAX-002 in 46 healthy adults aged 18 and older. The vaccine is designed to protect against newer COVID-19 variants like Omicron. Participants had already received a primary COVID-19 vaccine or booster at least 3 months before. The study checked for safety and immune response at different doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Covigenix VAX-002 (plasmid DNA vaccine)
What this could lead to
If successful, this could provide a safe and effective booster option targeting new COVID-19 variants like Omicron.
What could go wrong
This is an early-phase trial with only 46 participants, so results may not apply to larger populations. The vaccine is still experimental and may not provide strong or lasting protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centricity Research
Burlington, Ontario, L7M4Y1, Canada
-
Centricity Research
Toronto, Ontario, M4G3E8, Canada
-
Centricity Research
Toronto, Ontario, M9W4L6, Canada
-
Diex Recherche
Sherbrooke, Quebec, J1L0H8, Canada
-
Diex Recherche Quebec
Québec, Quebec, G1V4T3, Canada
-
University of Alberta
Edmonton, Alberta, Canada